HUP0400882A2 - Onkolitikus vírusterápia - Google Patents

Onkolitikus vírusterápia

Info

Publication number
HUP0400882A2
HUP0400882A2 HU0400882A HUP0400882A HUP0400882A2 HU P0400882 A2 HUP0400882 A2 HU P0400882A2 HU 0400882 A HU0400882 A HU 0400882A HU P0400882 A HUP0400882 A HU P0400882A HU P0400882 A2 HUP0400882 A2 HU P0400882A2
Authority
HU
Hungary
Prior art keywords
oncolytic virus
virus therapy
pharmaceutical composition
human leukocytes
platelets
Prior art date
Application number
HU0400882A
Other languages
English (en)
Inventor
William S. Groene
Jeffrey A. Miller
Stephen N. Mueller
Original Assignee
Wellstat Biologics Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Biologics Corporation filed Critical Wellstat Biologics Corporation
Publication of HUP0400882A2 publication Critical patent/HUP0400882A2/hu
Publication of HUP0400882A3 publication Critical patent/HUP0400882A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A találmányban humán daganatos betegek kezelési eljárását tettékközzé. A gyógyszerészeti összetételt a személybe beadják, mely humánleukocitákat és replikációra kompetens onkolítikus vírusokat tartalmazfiziológiásan elfogadható oldat szuszpenziójaként. Alternatívaként agyógyszerészeti összetétel onkolítikus vírussal fertőzött humánleukocitákat és vérlemezkéket tartalmaz. Ó
HU0400882A 2001-05-11 2002-05-09 Oncolytic virus therapy HUP0400882A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29005101P 2001-05-11 2001-05-11
PCT/US2002/014642 WO2002091997A2 (en) 2001-05-11 2002-05-09 Oncolytic virus therapy

Publications (2)

Publication Number Publication Date
HUP0400882A2 true HUP0400882A2 (hu) 2004-07-28
HUP0400882A3 HUP0400882A3 (en) 2011-01-28

Family

ID=23114328

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400882A HUP0400882A3 (en) 2001-05-11 2002-05-09 Oncolytic virus therapy

Country Status (13)

Country Link
US (3) US7122182B2 (hu)
EP (1) EP1385466B1 (hu)
JP (1) JP4916641B2 (hu)
CN (1) CN1332712C (hu)
AT (1) ATE500808T1 (hu)
AU (1) AU2002256510B2 (hu)
CA (1) CA2442648C (hu)
DE (1) DE60239394D1 (hu)
HU (1) HUP0400882A3 (hu)
IL (1) IL157504A0 (hu)
MX (1) MXPA03010278A (hu)
NZ (1) NZ527687A (hu)
WO (1) WO2002091997A2 (hu)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7780962B2 (en) * 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
AU4246900A (en) * 1999-04-15 2000-11-02 Pro-Virus, Inc. Treatment of neoplasms with viruses
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
CA2442648C (en) * 2001-05-11 2012-10-16 Pro-Virus, Inc. Oncolytic virus therapy
IL145397A0 (en) * 2001-09-12 2002-06-30 Yissum Res Dev Co Compositions and methods for treatment of cancer
US7615209B2 (en) 2001-09-12 2009-11-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions of NDV and methods of use thereof for treatment of cancer
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
US20050214266A1 (en) * 2004-03-12 2005-09-29 Oncolytics Biotech Inc. Combination of transplantation and oncolytic virus treatment
JP5054522B2 (ja) * 2004-08-20 2012-10-24 ヴィラリティクス リミテッド 血液ガンを治療するための方法および組成物
CA2617600A1 (en) 2005-08-01 2007-09-07 University Technologies International, Inc. Attenuated reovirus
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
US20070077231A1 (en) 2005-09-30 2007-04-05 Contag Christopher H Immune effector cells pre-infected with oncolytic virus
US20100086522A1 (en) * 2006-07-18 2010-04-08 Ottawa Health Research Institute Disparate suicide carrier cells for tumor targeting of promiscuous oncolytic viruses
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
WO2008144067A1 (en) * 2007-05-21 2008-11-27 Board Of Regents, University Of Texas System Methods and compositions for treatment of cancer using oncolytic rsv activity
CA2706750A1 (en) * 2007-11-27 2009-06-04 Ottawa Health Research Institute Amplification of cancer-specific oncolytic viral infection by histone deacetylase inhibitors
WO2010020247A1 (en) 2008-08-22 2010-02-25 Reapplix Aps Multilayered blood product
WO2010080909A1 (en) * 2009-01-08 2010-07-15 Yale University Compositions and methods of use of an oncolytic vesicular stomatitis virus
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
CA2689707A1 (en) 2009-11-16 2011-05-16 Jean-Simon Diallo Identification of the novel small molecule viral sensitizer vse1 using high-throughput screening
EP2764119A2 (en) 2011-10-05 2014-08-13 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
WO2013138522A2 (en) 2012-03-16 2013-09-19 Genelux Corporation Methods for assessing effectiveness and monitoring oncolytic virus treatment
WO2013158265A1 (en) 2012-04-20 2013-10-24 Genelux Corporation Imaging methods for oncolytic virus therapy
US20140140959A1 (en) 2012-10-05 2014-05-22 Aladar A. Szalay Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
CN108064282A (zh) 2014-10-14 2018-05-22 哈洛齐梅公司 腺苷脱氨酶-2(ada2)、其变体的组合物及使用其的方法
WO2016119051A1 (en) 2015-01-26 2016-08-04 Ottawa Hospital Research Institute Compositions and methods for viral sensitization
GB201504251D0 (en) 2015-03-13 2015-04-29 Virttu Biolog Ltd And University Of Sheffield The Oncolytic herpes simplex virus infected cells
US11078282B2 (en) 2016-04-15 2021-08-03 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
MX2018012472A (es) 2016-04-15 2019-08-12 Alpine Immune Sciences Inc Proteinas inmunomoduladoras variantes de ligando icos y sus usos.
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
CN110088127A (zh) 2016-07-28 2019-08-02 高山免疫科学股份有限公司 Cd155变体免疫调节蛋白及其用途
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
CA3034983A1 (en) 2016-10-03 2018-04-12 Ottawa Hospital Research Institute Compositions and methods for enhancing growth, spread, and oncolytic and immunotherapeutic efficacy of oncolytic rna viruses
CA3040296A1 (en) 2016-10-20 2018-04-26 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
WO2018148462A1 (en) 2017-02-09 2018-08-16 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and compositions and methods thereof
SI3596116T1 (sl) 2017-03-16 2024-02-29 Alpine Immune Sciences, Inc., Imunomodulatorni proteini različice pd-l1 in njihove uporabe
WO2018170026A2 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
CN110809581A (zh) 2017-03-16 2020-02-18 高山免疫科学股份有限公司 Pd-l2变体免疫调节蛋白及其用途
EP3697810A2 (en) 2017-10-18 2020-08-26 Alpine Immune Sciences, Inc. Variant icos ligand immunomodulatory proteins and related compositions and methods
EP3801584B1 (en) 2018-06-04 2023-09-27 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
WO2020047161A2 (en) 2018-08-28 2020-03-05 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
KR20210091740A (ko) 2018-11-06 2021-07-22 카리디 바이오테라퓨틱스, 인크. 세포-매개된 종양용해 바이러스 요법용 향상된 시스템
JP2022511735A (ja) 2018-11-21 2022-02-01 インダプタ セラピューティクス インコーポレイテッド ナチュラルキラー（ｎｋ）細胞サブセットの増大のための方法ならびに関連する組成物および方法
AU2019389151A1 (en) 2018-11-30 2021-06-10 Alpine Immune Sciences, Inc. CD86 variant immunomodulatory proteins and uses thereof
BR112021016728A2 (pt) 2019-02-27 2022-01-11 Actym Therapeutics Inc Bactérias imunostimulatórias projetadas para colonizar tumores, residentes em tumores células imunológicas e o microambiente tumoral
CN116368221A (zh) 2020-04-22 2023-06-30 因达普塔治疗公司 自然杀伤(nk)细胞组合物及其生成方法
WO2022147480A1 (en) 2020-12-30 2022-07-07 Ansun Biopharma, Inc. Oncolytic virus encoding sialidase and multispecific immune cell engager

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126132A (en) * 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer
ES2315595T3 (es) * 1993-04-30 2009-04-01 Wellstat Biologics Corporation Composiciones para tratar cancer con uso de virus.
US5595739A (en) * 1993-05-07 1997-01-21 Abbott Laboratories Hepatitis B virus mutants, reagents and methods for detection
US5910434A (en) * 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
ATE229810T1 (de) * 1996-10-11 2003-01-15 Univ California Krebs immuntherapie unter verwendung von tumorzellen kombiniert mit lymphozytmischungen
EP1032269B1 (en) * 1997-10-09 2007-08-29 Wellstat Biologics Corporation Treatment of neoplasms with interferon-sensitive, clonal viruses
US6177076B1 (en) * 1997-12-09 2001-01-23 Thomas Jefferson University Method of treating bladder cancer with wild type vaccinia virus
EP1061806A4 (en) * 1998-03-12 2001-09-12 Univ Pennsylvania PRODUCTIVE CELLS FOR REPLICATION-SELECTIVE VIRUSES FOR TREATING Vicious DISEASES
US6428968B1 (en) * 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
AU4246900A (en) * 1999-04-15 2000-11-02 Pro-Virus, Inc. Treatment of neoplasms with viruses
JP3639772B2 (ja) * 1999-06-30 2005-04-20 キヤノン株式会社 情報処理装置および印刷システムおよび印刷制御方法およびコンピュータが読み出し可能なプログラムを格納した記憶媒体
MXPA02002772A (es) 1999-09-17 2004-04-02 Pro Virus Inc Virus oncolitico.
US6270147B1 (en) * 2000-01-07 2001-08-07 Daimlerchrysler Corporation Drive arrangement for a power liftgate including clutching mechanism
US20020037543A1 (en) * 2000-06-26 2002-03-28 Atkins Harold L. Purging of cells using viruses
CA2442648C (en) 2001-05-11 2012-10-16 Pro-Virus, Inc. Oncolytic virus therapy

Also Published As

Publication number Publication date
US20090180994A1 (en) 2009-07-16
EP1385466A4 (en) 2005-10-12
ATE500808T1 (de) 2011-03-15
HUP0400882A3 (en) 2011-01-28
CN1332712C (zh) 2007-08-22
JP2004521938A (ja) 2004-07-22
US20050208024A1 (en) 2005-09-22
CN1514688A (zh) 2004-07-21
EP1385466B1 (en) 2011-03-09
NZ527687A (en) 2005-10-28
US7595042B2 (en) 2009-09-29
IL157504A0 (en) 2004-03-28
EP1385466A2 (en) 2004-02-04
US7122182B2 (en) 2006-10-17
CA2442648C (en) 2012-10-16
AU2002256510B2 (en) 2007-08-30
US20030077819A1 (en) 2003-04-24
DE60239394D1 (de) 2011-04-21
WO2002091997A3 (en) 2003-03-13
WO2002091997A2 (en) 2002-11-21
MXPA03010278A (es) 2004-12-06
JP4916641B2 (ja) 2012-04-18
US8137663B2 (en) 2012-03-20
CA2442648A1 (en) 2002-11-21

Similar Documents

Publication Publication Date Title
HUP0400882A2 (hu) Onkolitikus vírusterápia
DE69632256D1 (de) Antivirale proteine, dafür kodierende dna, und deren verwendung
HUP0402217A2 (hu) Platinaszármazékot tartalmazó gyógyászati készítmények
MY117892A (en) Therapeutic compounds
MXPA02006679A (es) Composicion farmaceutica.
CY1106430T1 (el) Φαρμακα για εισπνοη που πepιλαμβανουν βηταμιμητικα και αντιχολινepγικο
SG167657A1 (en) Novel medicament compositions based on tiotropium salts and on salmeterol salts
CY1106152T1 (el) Νεα ανοσογονα αντι-hiv (ανατοξινες), μεθοδοι παρασκευης και εφαρμογη στην προληψη και στην αγωγη του aids
DE60115029D1 (de) Pharmazeutische zusammensetzungen enthaltend cannabidiol-derivate
HK1068606A1 (en) Novel aminobenzoephenones
CY1105408T1 (el) Χρησιμοποιηση στελεχων του ιου parapox ovis για την παρασκευη αντιικων φαρμακων και φαρμακων κατα του καρκινου
IS7006A (is) Tvívetnis 3-piperidínóprópíófenon og lyf sem innihalda téð efnasambönd
CY1107231T1 (el) Υποκατεστημενα παραγωγα 4-αμινοκυκλοεξανολης
HUP9700806A2 (hu) Tianeptin-nátriumsó nyújtott felszabadulását biztosító, szájon át beadható mátrix tabletta és eljárás előállítására
PL1643999T3 (pl) Pirydoksamina do zastosowania w leczeniu nefropatii cukrzycowej w cukrzycy typu II
AP9801286A0 (en) Therapeutic compounds.
DE502005008500D1 (de) Verwendung von lavendelöl zur prophylaxe und behandlung von somatisierungsstörungen und von posttraumatischer stresserkrankung
HUP0301408A2 (hu) Szulodexid alkalmazása diabetikus vesebetegség kezelésére szolgáló orális gyógyszerkészítmény előállítására
SE0102887D0 (sv) New formulation
DE60308497D1 (de) Pulverzubereitungen zur inhalation
ATE295159T1 (de) Bupropion zur behandlung von viralen erkrankungen
ATE261732T1 (de) Pharmazeutische zusammensetzung, umfassend eukalyptus- und orangenöl
TR199901385T2 (xx) Piperidin t�revleri.
ATE395925T1 (de) Zytotoxische pharmazeutische zusammensetzung
Siddiqui et al. Therapeutic effect of a Unani formulation on hepatitis b surface antigen in chronic hepatitis b: a case series

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished